---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-068362"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:15:12.691439+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Entero Therapeutics amends rescission agreement adding accredited investor reps from ImmunogenX shareholders

## Summary
- Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.
- Shareholders also represent they have no need for liquidity, have evaluated investment risks, and are acquiring Membership Units for own account.
- Amendment effective July 15, 2025; parties include Entero Therapeutics, ImmunogenX LLC, and former ImmunogenX shareholders.
- Original Rescission Agreement, disclosed March 25, 2025, unwound the merger between Entero and ImmunogenX.

## SEC filing metadata
- accession: 0001104659-25-068362
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465925068362/0001104659-25-068362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465925068362/tm2521048d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-068362
- JSON: https://secwatch.observer/filing/0001104659-25-068362.json
- Plain text: https://secwatch.observer/filing/0001104659-25-068362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.